PF-06688992 / Pfizer - LARVOL DELTA

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=7; Completed; Sponsor: Memorial Sloan Kettering Cancer Center; Active, not recruiting ➔ Completed; Trial completion date: May 2020 ➔ Jan 2020; Trial primary completion date: May 2020 ➔ Jan 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=7; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Recruiting ➔ Active, not recruiting; N=20 ➔ 7

Clinical • Enrollment change • Enrollment closed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; N=40 ➔ 20

Clinical • Enrollment change